1e
19
1
49
2
2
18
1b
1d
18
3b
72
1d
2 29
1d
25
Richard Aplenc, MD, PhD, MSCE
88
72
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
28
68
3
61
Physican, The Children's Hospital of Philadelphia
11
Department: Pediatrics
4
1
b
1d
46
Contact information
54
4
3
3
3
2
4
b
1f
54
Colket Translational Research Building
13 Office 4060
39 3501 Civic Center Blvd
Philadelphia, PA 19104
26
13 Office 4060
39 3501 Civic Center Blvd
Philadelphia, PA 19104
2e
Office: 267-426-7252
30
7f
30
Email:
aplenc@chop.edu
12
aplenc@chop.edu
13
Education:
21 9 A.B. 15 (Classics) c
2d Princeton University, 1988.
21 5 c
5a University of Pennsylvania, Post-Baccalaureate Pre-Health Program, 1989.
21 7 MD c
2f University of Virginia, 1994.
21 9 MSCE 34 (Clinical Epidemiology and Biostatistics) c
33 University of Pennsylvania, 2002.
21 8 PhD 19 (Epidemiology) c
33 University of Pennsylvania, 2011.
c
3
3
3
3
8a
Permanent link21 9 A.B. 15 (Classics) c
2d Princeton University, 1988.
21 5 c
5a University of Pennsylvania, Post-Baccalaureate Pre-Health Program, 1989.
21 7 MD c
2f University of Virginia, 1994.
21 9 MSCE 34 (Clinical Epidemiology and Biostatistics) c
33 University of Pennsylvania, 2002.
21 8 PhD 19 (Epidemiology) c
33 University of Pennsylvania, 2011.
c
2 29
21
1e
1d
24
2b
29
27
23
22d Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, Moreloose BD, Dworzak MN, Fogelstrand L, Gibson BE, Goemans BF, Hasle H, Hirsch BA, Kaspers GJ, Klusmann J, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM: Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel. Blood Page: blood.2024027904, Oct 2025 Notes: doi: 10.1182/blood.2024027904.
11d Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT: Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients with Hematologic Malignancy. J Pediatric Infect Dis Soc. 40 Oct 2025 Notes: doi: 10.1093/jpids/piaf091.
1c8 Zheng DJ, Hettinger G, Bender JD, Boulter AC, Cao L, Elgarten CW, Fisher BT, Gathers C, Huang YV, Ko J, Leger KJ, Li Y, Myers R, Narayan HK, Ortiz J, Seif AE, Vasileiadi E, Aplenc R, Getz KD: National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia. JAMA Oncol Page: e254365, Oct 2025 Notes: doi: 10.1001/jamaoncol.2025.4365.
11c Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT: Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy. J Pediatric Infect Dis Soc 48 14(10), Oct 2025 Notes: doi: 10.1093/jpids/piaf091.
22d Seif AE, McDonough SL, Becker-Haimes EM, Oranges KE, Clerico D, Hartman J, Rodock K, Schwartz LA, Elgarten CW, Myers RM, Puszczynski RO, Rheingold SR, Stern JW, Jubelirer TF, Armideo EA, Evageliou NF, Randall RJ, Bernt KM, Reilly AF, Tasian SF, Diamant RK, Fisher BT, Getz KD, Aplenc R: AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy. JCO Oncol Pract Page: OP2500314, Sept 2025 Notes: doi: 10.1200/OP-25-00314.
261 Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD: Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst Page: djaf234, Aug 2025 Notes: doi: 10.1093/jnci/djaf234.
1ca Huang BL, Meyer LK, Alonzo TA, Wang Y, Lamble AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, Loken MR, Meshinchi S, Chewning JH, Woods WG, Horan JT: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. J Clin Oncol 43(17): 1961-1971, Jun 2025 Notes: doi: 10.1200/JCO-24-01841.
2a3 Newman H, Lee SHR, Polonen P, Shraim R, Li Y, Liu H, Aplenc R, Bandyopadhyay S, Chen C, Devidas M, Diorio C, Dunsmore K, Elghawy O, Elhachimi A, Fuller T, Gupta S, Hall J, Hughes AD, Hunger SP, Loh ML, Martinez Z, McCoy MF, Mullen CG, Pounds SB, Raetz E, Seffernick AE, Shi G, Sussman J, Tan K, Uppuluri L, Vincent TL, Wang'ondu R, Winestone LE, Winter SS, Wood BL, Wu G, Xu J, Yang W, Mullighan CG, Yang JJ, Bona K, Teachey DT: Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia. Blood Cancer Discov May 2025 Notes: doi: 10.1158/2643-3230.BCD-25-0049.
27a Myers RM, DiNofia AM, Li Y, Diorio C, Liu H, Wertheim G, Fraietta JA, Gonzalez V, Plesa G, Siegel DL, Iannone E, Shinehouse L, Brogdon JL, Taylor C, Jadlowsky JK, Hexner EO, Engels B, Baniewicz D, Callahan C, Ruella M, Aplenc R, Leahy AB, McClory SE, Rheingold SR, Wray L, June CH, Maude SL, Frey NV, Grupp SA: CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. J Immunother Cancer 13(4): e011549, Apr 2025 Notes: doi: 10.1136/jitc-2025-011549.
2c
7
1d
1f
Selected Publications
28c Naik S, Aplenc R, Baumeister SH, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velaquez Gill SI: International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv 9(23): 6047-6058, Dec 2025 Notes: doi: 10.1182/bloodadvances.2025017011.22d Zwaan CM, Tasian SK, Aplenc R, Brodersen LE, Buldini B, Moreloose BD, Dworzak MN, Fogelstrand L, Gibson BE, Goemans BF, Hasle H, Hirsch BA, Kaspers GJ, Klusmann J, Kutny MA, Lehrnbecher T, Locatelli F, Meshinchi S, Petit A, Pigazzi M, Tierens A, Kolb EA, Reinhardt D, Tomizawa D, Cooper TM: Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel. Blood Page: blood.2024027904, Oct 2025 Notes: doi: 10.1182/blood.2024027904.
11d Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT: Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients with Hematologic Malignancy. J Pediatric Infect Dis Soc. 40 Oct 2025 Notes: doi: 10.1093/jpids/piaf091.
1c8 Zheng DJ, Hettinger G, Bender JD, Boulter AC, Cao L, Elgarten CW, Fisher BT, Gathers C, Huang YV, Ko J, Leger KJ, Li Y, Myers R, Narayan HK, Ortiz J, Seif AE, Vasileiadi E, Aplenc R, Getz KD: National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia. JAMA Oncol Page: e254365, Oct 2025 Notes: doi: 10.1001/jamaoncol.2025.4365.
11c Vasileiadi E, Elgarten CW, Getz KD, Aplenc R, Fisher BT: Fluoroquinolone Susceptibility and Comparative Outcomes of Gram-negative Bloodstream Infection in Pediatric Patients With Hematologic Malignancy. J Pediatric Infect Dis Soc 48 14(10), Oct 2025 Notes: doi: 10.1093/jpids/piaf091.
22d Seif AE, McDonough SL, Becker-Haimes EM, Oranges KE, Clerico D, Hartman J, Rodock K, Schwartz LA, Elgarten CW, Myers RM, Puszczynski RO, Rheingold SR, Stern JW, Jubelirer TF, Armideo EA, Evageliou NF, Randall RJ, Bernt KM, Reilly AF, Tasian SF, Diamant RK, Fisher BT, Getz KD, Aplenc R: AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy. JCO Oncol Pract Page: OP2500314, Sept 2025 Notes: doi: 10.1200/OP-25-00314.
261 Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD: Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst Page: djaf234, Aug 2025 Notes: doi: 10.1093/jnci/djaf234.
1ca Huang BL, Meyer LK, Alonzo TA, Wang Y, Lamble AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, Loken MR, Meshinchi S, Chewning JH, Woods WG, Horan JT: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. J Clin Oncol 43(17): 1961-1971, Jun 2025 Notes: doi: 10.1200/JCO-24-01841.
2a3 Newman H, Lee SHR, Polonen P, Shraim R, Li Y, Liu H, Aplenc R, Bandyopadhyay S, Chen C, Devidas M, Diorio C, Dunsmore K, Elghawy O, Elhachimi A, Fuller T, Gupta S, Hall J, Hughes AD, Hunger SP, Loh ML, Martinez Z, McCoy MF, Mullen CG, Pounds SB, Raetz E, Seffernick AE, Shi G, Sussman J, Tan K, Uppuluri L, Vincent TL, Wang'ondu R, Winestone LE, Winter SS, Wood BL, Wu G, Xu J, Yang W, Mullighan CG, Yang JJ, Bona K, Teachey DT: Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic Leukemia. Blood Cancer Discov May 2025 Notes: doi: 10.1158/2643-3230.BCD-25-0049.
27a Myers RM, DiNofia AM, Li Y, Diorio C, Liu H, Wertheim G, Fraietta JA, Gonzalez V, Plesa G, Siegel DL, Iannone E, Shinehouse L, Brogdon JL, Taylor C, Jadlowsky JK, Hexner EO, Engels B, Baniewicz D, Callahan C, Ruella M, Aplenc R, Leahy AB, McClory SE, Rheingold SR, Wray L, June CH, Maude SL, Frey NV, Grupp SA: CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. J Immunother Cancer 13(4): e011549, Apr 2025 Notes: doi: 10.1136/jitc-2025-011549.
2c